Top

Published in:

01-11-2010 | Clinical Study – Patient Study

Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing

Authors: Yasuo Sugita, Mizuhiko Terasaki, Daisuke Niino, Koichi Ohshima, Arakawa Fumiko, Minoru Shigemori, Yasuharu Sato, Naoko Asano

Published in: Journal of Neuro-Oncology | Issue 2/2010

Abstract

Epstein–Barr virus (EBV) has been implicated in the pathogenesis of primary central nervous system lymphomas (PCNLs) in immunocompetent hosts. To investigate the role of EBV in the pathogenesis of PCNLs in immunocompetent hosts, this study assessed six PCNL cases (elderly male immunocompetent patients; age ≥60 years) histologically and immunohistochemically, and an EBV genetic study was performed. Histologically, all cases were diagnosed as diffuse large B-cell lymphoma with extensive necrosis. In all six cases, PCNL cells showed immunohistochemical positivity for latent membrane protein 1 (LMP-1) and Epstein-Barr nuclear 2 (EBNA2). Lymphoma cells also showed positive signals for EBV-encoded small RNAs (EBERs) on in-situ hybridization. EBV subtyping-PCR analysis demonstrated that one case was EBNA 2B type and the other five cases were EBNA 2A type, and two cases were EBV wild-type and four cases showed 30-bp LMP-1 deletion by PCR analysis. It is therefore possible that LMP gene deletion or EBNA-2 strain type are important in the tumorigenesis of EBV-positive PCNLs. In addition, EBV-positive PCNLs in immunocompetent hosts may be related to immunological deterioration derived from the aging process.

DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643–4648CrossRefPubMed

Deckert M, Paulus W (2007) Malignant lymphomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer Press, Lyon, pp 188–192

Rouah E, Rogers BB, Wilson DR, Kirkpatrick JB, Buffone GJ (1990) Demonstration of Epstein-Barr virus in primary central nervous system lymphomas by the polymerase chain reaction and in situ hybridization. Hum Pathol 21:545–550CrossRefPubMed

List AF, Greer JP, Cousar JP, Johnson DH, Greco FA, Volsky DJ, Purtilo DT (1990) Primary brain lymphomas in the immunocompetent host: relation to Epstein-Barr virus. Modern Pathol 3:609–612

Nakhleh RE, Manivel JC, Copenhaver CM, Sung JH, Strickler JG (1991) In situ hybridization for the detection of Epstein-Barr virus in central nervous system lymphomas. Cancer 67:444–448CrossRefPubMed

O’Neill BP, Vernino S, Dogan A, Giannini C (2007) EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol 9:364–369CrossRefPubMed

Kleinschmidt-DeMasters BK, Damek DM, Lillehei KO, Dogan A, Giannini C (2008) Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications. J Neuropathol Exp Neurol 67:1103–1111CrossRefPubMed

Zhang L, Zhang J, Lambert Q, Der CJ, Del Valle L, Miklossy J, Khalili K, Zhou Y, Pagano JS (2004) Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties. J Virol 78:12987–12995CrossRefPubMed

Hu L-F, Chen F, Zheng X, Ernberg I, Cao S-L, Christensson B, Klein G, Winberg G (1993) Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 8:1575–1583PubMed

10.

Shibata D, Weiss LM, Hernandez AM, Nathwani BN, Bernstein L, Levine AM (1993) Epstein-Barr virus-associated non-Hodgkin’s lymphoma in patients infected with the human immunodeficiency virus. Blood 81:2102–2109PubMed

11.

Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M (1996) Epstein-Barr virus latent membrane protein-1 oncogene deletion: correlation with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 88:242–251PubMed

12.

Tabata Y, Hibi S, Teramura T, Kuriyama K, Yagi T, Todo S, Sawada T, Imashuku S (2000) Molecular analysis of latent membrane protein 1 in patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Leuk Lymphoma 38:373–380

13.

Yamato H, Ohshima K, Suzumiya J, Kikuchi M (2001) Evidence for local immunosuppression and demonstration of c-myc amplification in pyothorax-associated lymphoma. Histopathology 39:163–171CrossRefPubMed

14.

MacMahon EM, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC, Ambinder RF (1991) Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338:969–973CrossRefPubMed

15.

Guterman KS, Hair LS, Morgello S (1996) Epstein-Barr virus and AIDS-related primary central nervous system lymphoma. Viral detection by immunohistochemistry, RNA in situ hybridization, and polymerase chain reaction. Clin Neuropathol 15:79–86PubMed

16.

Ohshima K, Tutiya T, Yamaguchi T, Suzuki K, Suzumiya J, Kawasaki C, Haraoka S, Kikuchi M (2002) Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&R) cells in Hodgkin disease: relation with expression of CXC and CC chemokines on H&R cells. Int J Cancer 98:567–572CrossRefPubMed

17.

Ramasamy I, Brisco M, Morley A (1992) Improved PCR method for detecting monoclonal Immunoglobulin heavy chain rearrangement in B cell neoplasms. J Clin Pathol 45:770–775CrossRefPubMed

18.

Reed TJ, Reid A, Wallberg K, O’Leary TJ, Frizzera G (1993) Determination of B-cell clonality in paraffin-embedded lymph nodes using the polymerase chain reaction. Diag Mol Pathol 2:42–49

19.

Ohshima K, Suzumiya J, Kanda M, Haraoka S, Kawasaki C, Shimazaki K, Kikuchi M (1999) Genotypic and phenotypic alternations in Epstein-Barr virus-associated lymphoma. Histopathology 35:539–550CrossRefPubMed

20.

Hudson GS, Bankier AT, Satchwell SC, Barrell BG (1985) The short unique region of the B95-8 Epstein-Barr virus genome. Virology 147:81–98CrossRefPubMed

21.

Nomura Y, Lavu EK, Muta K, Niino D, Takeshita M, Hirose S, Nakamura S, Yoshino T, Kikuchi M, Ohshima K (2008) Histological characteristics of 21 Papua New Guinean children with high-grade B-cell lymphoma, which is frequently associated with EBV infection. Pathol Int 58:695–700CrossRefPubMed

22.

Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, Yokoi T, Kojima M, Kamiya Y, Taji H, Kagami Y, Ogura M, Saito H, Morishima Y, Nakamura S (2003) Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathological study of 22 patients. Am J Surg Pathol 27:16–26CrossRefPubMed

23.

Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, Ohshima K, Suzumiya J, Nakamura N, Abe M, Ichimura K, Sato Y, Yoshino T, Naoe T, Shimoyama Y, Kamiya Y, Kinoshita T, Nakamura S (2007) Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 13:5124–5132CrossRefPubMed

24.

Takegawa S, Jin Z, Nakayama T, Oyama T, Hieshima K, Nagakubo D, Shirakawa A-K, Tsuzuki T, Nakamura S, Yoshie O (2008) Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder. Cancer Sci 99:296–302CrossRefPubMed

25.

Chan KH, Ng MH, Seto WH, Peiris JS (2001) Epstein-Barr virus (EBV) DNA in sera of patients with primary EBV infection. J Clin Microbiol 39:4152–4154CrossRefPubMed

26.

Takeuchi K, Tanaka-Taya K, Kazuyama Y, Ito YM, Hashimoto S, Fukayama M, Mori S (2006) Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol Int 56:112–116CrossRefPubMed

27.

Soussain C, Muldoon LL, Varallyay C, Jahnke K, DePaula L, Neuwelt EA (2007) Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. Clin Cancer Res 13:2504–2511CrossRefPubMed

28.

Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF, Caligiuri MA (2003) Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 63:965–971PubMed

Title: Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing
Authors: Yasuo Sugita
Mizuhiko Terasaki
Daisuke Niino
Koichi Ohshima
Arakawa Fumiko
Minoru Shigemori
Yasuharu Sato
Naoko Asano
Publication date: 01-11-2010
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0191-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Inverse association of PPARγ agonists use and high grade glioma development

Erratum to: A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas

Natural history and management of low-grade glioma in NF-1 children

Treatment-induced leukoencephalopathy in primary CNS lymphoma presenting as lower body parkinsonism

Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?

Olfactory ensheathing cell tumour: case report and literature review